

## Inter-Method Differences in the Measurement of Some Specific Plasma Proteins: Commutability of Control Materials

Laura Arcangeli<sup>1</sup>, Paolo Cueroni<sup>2</sup>, Carlo Franzini<sup>3</sup>, Giovanna Galletta<sup>3</sup>, Alessandra Moschini<sup>3</sup> and Luisa Scapellato<sup>3</sup>

<sup>1</sup> Laboratorio Analisi, Ospedale Caduti Bollatesi, Bollate (Milano), Italy

<sup>2</sup> Laboratorio Analisi, Ospedale C. Ondoli, Angera (Varese), Italy

<sup>3</sup> Università di Milano, Istituto di Scienze Biomediche, Ospedale L. Sacco, Milano, Italy

**Summary:** We compared the inter-method differences shown by control materials and by patients' sera for the measurement of some plasma proteins in the same pair of analytical systems. Sets of 100 to 110 samples of patients' sera and of 18-19 control materials, including the recently available CRM 470, were assayed with up to five automatic analytical systems, in two different experiments. About 5500 values were produced and assessed statistically. Materials (either patients' sera or control materials) were considered non-commutable (i. e. exhibiting significantly different inter-method behaviour) when their distance from the regression line in a stated pair of methods exceeded 3 standard deviations. According to this criterion, less than 1.5% of the patients' sera, and an even lower proportion of control materials were non-commutable. However, the inter-method behaviour of control materials was usually slightly different from that of patients' sera. Some systematic inter-method difference in the measurements on patients' sera may therefore exist, even though inter-method equivalence has been demonstrated with control materials.

### Introduction

Plasma protein measurements show great variability between laboratories (1), mainly due to calibration problems (1, 2). The purpose of calibration is to ensure that the results from patients' sera are as close as possible to the "true" value, and that the results from different procedures are as close as possible to each other. In practice, calibration is performed using "materials", mostly provided by industry; for such materials to serve the expected purpose, they have to show inter-method properties comparable to those of patients' sera. This characteristic, known as *commutability*, was first studied for enzyme materials (3). Occurrence of non-commutability has been reported for a variety of non-enzymatic components (4-6).

Here we report the results from two experiments, using different analytical systems, and planned to assess the commutability of a number of commercial control materials for the immunoassay of certain serum proteins. The two experiments involved a variable number of laboratories (two to three), analytical systems (four to five), serum proteins (two to four), and control materials (eighteen to nineteen). The second experiment also included a certified reference material (CRM 470).

### Materials and Methods

Different sets of from 100 to 110 samples of fresh patients' serum, covering wide intervals of concentration, were used in the two experiments. A total of 26 commercial control materials, either lyophi-

lized or liquid, were also used (tab. 1). The CRM 470 was obtained by BCR, Brussels (courtesy of Beckman Analytical, Milano).

Immunoglobulins A, G and M (IgA, IgG, IgM) and transferrin were measured in the patients' sera (in duplicate) and in the control materials (four replicates), using five automatic systems, based on immuno-turbidimetry (AU 560, Olympus; and Specific Plus, Kone) or immunonephelometry (QM 300, Kallestad; BNA, Behring; and APS 360, Beckman). Each system was operated with the reagents and the calibrators supplied by the respective manufacturer. Between the first and the second experiment some modifications in the operating protocol of the AU 560 system were introduced, including modified anti-sera dilution ratios, modified sample volume fractions, and new lots of anti-sera and calibrators.

Analytical imprecision was calculated from duplicate results on patients' sera. Mean values from duplicate or quadruplicate measurements were used for further calculations. The inter-method relationship in the measurement of patients' sera with pairs of methods was assessed by means of linear regression, calculated according to the standardized principal component model (8); the residual standard deviation was computed as a measure of the dispersion around the line. Results from the AU 560 system were consistently assigned the x-axis, in order to have a common comparison basis for the other systems.

For the assessment of commutability,  $y'$ -values were computed from each set of x-values (patients' sera) using the relevant regression equation; the differences  $[y-y']$  (residuals) were divided by their standard deviation to yield the "normalized residuals". Normalized residuals were also calculated for the control materials. Any material (patient serum or control material) showing a normalized residual outside the  $\pm 3$  interval was considered non-commutable (9). About 5500 single analytical values were produced: none was excluded from statistical calculations.

### Results

Table 2 shows the within-run imprecision of the five analytical systems at different protein concentration values.

Results of the methods comparison on patients' sera are shown in figures 1 and 2; the statistical evaluation of the inter-methods relationships is shown in table 3.

The distribution quantities (mean, SD, and number outside the  $\pm 3$  interval) of the two populations of normalized residuals, from patients' sera and control materials

respectively, are listed in table 4; the normalized residuals of the CRM 470 are listed in the table on a separate column.

In figure 3 the inter-method behaviour of the control materials and of the patients' sera are compared for some representative pairs of methods. Two examples of

**Tab. 1** Control materials used in the two experiments.

Exp.	Material	Manufacturer	Physical state	Matrix	Specific for serum proteins
I & II	Monitrol I	Baxter	lyophilized	human	no
I & II	Monitrol II	Baxter	lyophilized	human	no
I & II	Human Protein Reference Serum	Orion	lyophilized	human	yes
I & II	Precinorm U	Boehringer	lyophilized	human	no
I & II	Precipath U	Boehringer	lyophilized	human	no
I & II	Precinorm Protein	Boehringer	liquid	human	yes
I	Seronorm Human	Nycomed	lyophilized	human	no
I	Sernorm Protein	Nycomed	lyophilized	human	yes
I & II	Bio-rad 1	Biorad	lyophilized	human	no
I & II	Bio-rad 2	Biorad	lyophilized	human	no
I & II	Bio-rad 3	Biorad	lyophilized	human	no
I	Bio-rad 4	Biorad	lyophilized	human	no
I & II	Ortho Cortina	Ortho	lyophilized	human	no
I & II	Ortho Cervinia	Ortho	lyophilized	human	no
I	Decision Level 1	Beckman	liquid	human	no
I	Decision Level 2	Beckman	liquid	human	no
I	Decision Level 3	Beckman	liquid	human	no
I	Kontrollagen L	Behring	lyophilized	human	no
I	Kontrollagen LP	Behring	lyophilized	human	no
II	N/T	Behring	liquid	human	yes
II	CRM 470	BCR	lyophilized	human	yes
II	Vigil PRx 1	Beckman	liquid	human	yes
II	Vigil PRx 2	Beckman	liquid	human	yes
II	Vigil PRx 3	Beckman	liquid	human	yes
II	Liquicheck 1	Biorad	liquid	human	yes
II	Liquicheck 2	Biorad	liquid	human	yes


**Tab. 2** Analytical (within-series) imprecision of the five systems, from duplicate results, at two concentration levels (Lo and Hi).

Protein	System	Exp.	n		Mean (g/l)		CV (%)	
			Lo	Hi	Lo	Hi	Lo	Hi
IgA	AU 560	I	56	44	12.2	28.9	1.23	1.86
IgA	AU 560	I	55	45	1.95	6.54	1.66	1.02
IgM	AU 560	I	55	45	1.18	3.63	0.80	1.45
IgM	AU 560	II	55	55	1.67	4.87	3.31	4.64
Transferrin	AU 560	I	51	49	1.94	3.08	2.32	2.31
Transferrin	AU 560	II	55	55	1.73	3.41	3.62	3.88
IgG	QM 300	I	55	45	13.3	30.9	2.83	2.30
IgA	QM 300	I	52	48	1.96	7.58	3.26	3.19
IgM	QM 300	I	53	47	0.92	3.25	4.30	5.38
IgM	QM 300	II	55	55	1.29	3.78	3.90	3.04
Transferrin	QM 300	I	43	57	2.25	3.49	1.85	2.39
Transferrin	QM 300	II	55	55	1.82	3.48	5.60	5.25
IgG	SPECIFIC	I	50	50	13.7	30.8	1.56	2.19
IgA	SPECIFIC	I	46	54	1.67	6.68	3.35	4.35
IgM	SPECIFIC	I	53	47	1.13	4.51	5.24	2.47
Transferrin	SPECIFIC	I	50	50	2.23	3.40	1.34	1.37
IgM	BNA	I	56	44	1.62	5.57	3.29	1.46
IgM	BNA	II	55	55	2.11	6.32	1.62	3.46
Transferrin	BNA	II	55	55	1.91	3.62	3.30	2.85
IgM	APS 360	II	55	55	1.48	4.31	1.83	1.53
Transferrin	APS 360	II	55	55	1.70	3.33	1.74	1.48

inter-method behaviour of control materials overlapping that of patients' sera (diagrams 3a and 3b), and two examples of inter-method behaviour of control materials systematically different from that of patients' sera (diagrams 3c and 3d) are shown. Only two materials (circled in diagram 3d) show lack of commutability, according to the criterion chosen.

## Discussion


Casual and systematic inter-method differences in the measurement of some plasma proteins are confirmed by our results (fig. 1 and 2, tab. 3). Whilst it seems reasonable to speculate that matrix effects and/or molecular heterogeneity are mainly responsible for the former, calibration problems appear to be mainly responsible for



**Fig. 1** Method comparison on patients' sera (from 100 to 110 samples): results from experiment I. For uniform comparison, the values from the AU 560 system were consistently assigned the x-axis, and the results from the alternative analytical systems were

assigned the y-axis. The regression lines were calculated according to the standardized principal component model.

(— □): QM 300  
(..... +): Specific  
(-- X): BNA



**Fig. 2** Same as figure 1, results from experiment II.

(— □): QM 300  
(..... +): Specific  
(-- X): BNA

the latter (slope values different from 1). As a matter of fact, mathematical manipulation of the results, using CRM 470-derived factors supplied by the manufacturers, has been shown to substantially improve the inter-method comparability of results in the measurement of a number of serum proteins in a sample-group of reference individuals (10). Previous results on the effect of the calibration procedure (1), and the expected practical impact of the CRM 470 (2) are thereby confirmed.

In this work, by comparing the inter-method behaviour of control materials and of sets of patients' sera over

wider concentration intervals, we have assessed the intrinsic characteristic of the "materials" commonly referred to as commutability. According to a previously suggested criterion (9), most of the materials showed commutable, such a low rate of non-commutability events (< 1.5%) being partly due to the large variability of the inter-method differences exhibited by patients' sera (5). However (tab. 4), the normalized residuals from patients' sera were distributed as theoretically expected (mean = 0; standard deviation = 1), whilst those from the control materials were distributed within narrower limits (standard deviation < 1) but frequently not

**Tab. 3** Linear regression analysis (standardized principal component) of the results from systems comparison, in the assay of patients' sera. Results from the AU 560 system were consistently

assigned the x-axis, those from the compared system the y-axis. Residual standard deviations ( $S_{yx}$ ) are shown as a measure of the dispersion around the line.

Protein	Compared system (y-axis)	Exp.	n	$S_{yx}$ (g/l)	Interval of x-values (g/l)	y-Intercept (g/l)	Slope $\pm$ S. E.
IgG	QM 300	I	100	1.22	4.33 $\div$ 44.21	+ 0.48	1.06 $\pm$ 0.012
IgG	SPECIFIC	I	100	2.14	4.33 $\div$ 44.21	+ 0.99	1.08 $\pm$ 0.022
IgA	QM 300	I	100	0.53	0.68 $\div$ 12.28	- 0.68	1.33 $\pm$ 0.020
IgA	SPECIFIC	I	100	0.61	0.68 $\div$ 12.28	- 0.58	1.23 $\pm$ 0.023
IgM	QM 300	I	100	0.36	0.40 $\div$ 8.69	- 0.28	1.00 $\pm$ 0.024
IgM	SPECIFIC	I	100	0.52	0.40 $\div$ 8.69	- 0.42	1.38 $\pm$ 0.034
IgM	BNA	I	100	0.42	0.40 $\div$ 8.69	- 0.35	1.62 $\pm$ 0.028
IgM	QM 300	II	110	0.36	0.32 $\div$ 8.56	- 0.18	0.83 $\pm$ 0.018
IgM	BNA	II	110	0.56	0.32 $\div$ 8.56	- 0.24	1.36 $\pm$ 0.028
IgM	APS 360	II	110	0.30	0.32 $\div$ 8.56	- 0.11	0.92 $\pm$ 0.015
Transferrin	QM 300	I	100	0.18	0.93 $\div$ 4.29	+ 0.26	1.09 $\pm$ 0.025
Transferrin	SPECIFIC	I	100	0.27	0.93 $\div$ 4.29	+ 0.26	1.02 $\pm$ 0.039
Transferrin	QM 300	II	110	0.20	0.50 $\div$ 4.44	+ 0.04	1.02 $\pm$ 0.019
Transferrin	BNA	II	110	0.15	0.50 $\div$ 4.44	+ 0.08	1.04 $\pm$ 0.014
Transferrin	APS 360	II	110	0.16	0.50 $\div$ 4.44	+ 0.02	0.97 $\pm$ 0.015

**Tab. 4** Assessment of commutability: distribution quantities of the two populations of normalized residuals from patients' sera (n from 100 to 110) and control materials (n from 17 to 19). The

normalized residuals from the CRM 470 are tabulated in a separate column for comparison. Results from each alternative system were compared with the AU 560 system.

Protein	System compared	Exp.	Normalized residuals from							Line
			Patients' sera			Control materials			CRM 470	
			m	SD	outside $\pm$ 3	m	SD	outside $\pm$ 3		
IgG	QM 300	I	0.00	1.00	0	-0.10	0.28	0	-	1
IgG	SPECIFIC	I	0.00	1.00	0	-0.12	0.54	0	-	2
IgA	QM 300	I	0.00	1.00	2	0.10	0.52	0	-	3
IgA	SPECIFIC	I	0.00	1.00	1	0.30	0.26	0	-	4
IgM	QM 300	I	0.01	1.00	3	-0.25	0.44	0	-	5
IgM	QM 300	II	-0.01	1.00	2	0.63	0.35	0	0.83	6
IgM	SPECIFIC	I	-0.01	1.00	1	-0.54	0.55	0	-	7
IgM	BNA	I	0.01	1.00	2	0.58	0.52	0	-	8
IgM	BNA	II	0.00	1.00	2	1.16	0.47	0	0.74	9
IgM	APS 360	II	0.00	1.00	1	0.82	0.56	0	0.84	10
Transferrin	QM 300	I	0.01	1.00	1	-2.02	0.55	0	-	11
Transferrin	QM 300	II	-0.02	1.00	3	1.80	0.98	3	2.12	12
Transferrin	SPECIFIC	I	-0.02	1.00	1	-1.60	0.50	0	-	13
Transferrin	BNA	II	0.04	1.00	1	0.90	1.44	3	1.03	14
Transferrin	APS 360	II	0.00	1.00	2	0.68	1.00	1	1.50	15




Fig. 3 Representative examples of the inter-method behaviour of control materials (crosses) compared with patients' sera (regression lines, standardized principal component model). Diagrams a, b, c, and d, correspond, respectively, to lines 1, 3, 9, and 14 of table 4.

around 0. These data mean that the sample-group of materials shows inter-method changes more homogeneous than the sample-group of patients' sera. Nevertheless, and in spite of low frequency of non-commutability events, the two groups differ from each other in their inter-method behaviour: the CRM is closer to the control materials than to patients' sera. Similar behaviour was shown by the control materials for cholesterol measurement (11).

These findings suggest that, in most cases, the inter-method differences measured with either a control material or a fresh serum sample are expected to show statistically significant agreement. Nevertheless, when many of the tested materials (including the CRM 470) are used to directly check for (control), or to pursue (calibration)

In diagrams a and b the points distribute on the two sides of the line, in diagram c and d they distribute mainly or exclusively on one side of the line. In diagram d two points outside the line by more than 3 residual standard deviations are circled.

consistency in measurements by different methods, some residual differences may still exist when these methods are applied to fresh sera.

Therefore, transfer of accuracy and accurate inter-method comparison are best performed with protocols that also include direct method comparison on a large series of split serum samples (12, 13). Alternatively, the commutability of the materials should be verified. Although some of the differences observed between experiments I and II may be due to differences in the sets of patients' sera, it seems that both the inter-method differences and the degree of commutability of the control materials are sensitive to variations in the assay protocol. This further suggests the need for a frequent check of such properties.

## References

- Bullock DG, Dumont G, Vassault A, Aguzzi F, Chambers RE, Milford Ward A, et al. Immunochemical assays of serum proteins: a European external quality assessment survey and the effects of calibration procedures on interlaboratory agreement. *Clin Chim Acta* 1990; 187:21-36.
- Whicher JT, Ritchie RF, Johnson AM, Baudner S, Bienvenue J, Bliirup-Jensen S, et al. New international reference preparation for proteins in human serum (RPPHS). *Clin Chem* 1994; 40:934-8.
- Fasce CF, Jr, Rej R, Copeland WH, Vanderlinde RE. A discussion of enzyme reference materials: applications and specifications. *Clin Chem* 1973; 19:5-9.
- Rej R, Jenny RW, Breaudiere JP. Quality control in clinical chemistry: characterization of reference materials. *Talanta* 1984; 31:851-62.
- Franzini C. Commutability of reference materials in clinical chemistry. *JIFCC* 1993; 5:186-93.
- Rej R. Accurate enzyme activity measurements. Two decades of development of the commutability of enzyme quality control materials. *Arch Pathol Lab Med* 1993; 117:352-64.
- Galletta G, Arcangeli L, Scapellato L. Commutability of control materials in immunonephelometric and immunoturbidimetric measurement of some specific serum proteins [abstract]. *Eur J Clin Chem Clin Biochem* 1994; 32:A17.

8. Haeckel R, Bablok W, Goldschmidt HMJ, Müller HAG, Meyers W, Stockmann W, et al. Recommendations for the biometrical evaluation of method comparison results from patients' samples. *DG Klin Chem Mitteilungen* 1994; 25:32-4.
9. Van Helden WCH, Visser RWJ, Van Den Bergh FAJ-TM, Souverijn JHM. Comparison of inter-method analytical variability of patient sera and commercial quality control sera. *Clin Chim Acta* 1979; 93:335-47.
10. Aguzzi F, Gasparro C, Somenzini M, Calatroni S. I nuovi valori di riferimento per le 14 sieroproteine del CRM 470 (RPPHS). Dati preliminari. *Biochim Clin* 1994; 18:612-6.
11. Franzini C, Luraschi P. Commutability of control materials in cholesterol measurements. *Scand J Clin Lab Invest* 1993; 53:51-5.
12. Miller WG, Rhodes DJ, Moore CJ. A calibration protocol for serum-based secondary standards. *Clin Chem* 1982; 11:2195-200.
13. Cooper GR, Myers GL. Reference system for cholesterol measurements. *Scand J Clin Lab Invest* 1990; 198 Suppl 50:27-1.

*Received July 3/October 5, 1995*

Corresponding author: Prof. Carlo Franzini, Università di Milano, Istituto di Scienze Biomediche, Ospedale L. Sacco, Via G. B. Grassi, 74, I-20157 Milano, Italy